Michael John Zobel

Michael John Zobel

Auto-generated profile, based on publicly available information

Michael John Zobel

Division of Pediatric Surgery, Department of Surgery, Children’s Hospital Los Angeles, Los Angeles, California, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
CGClaire E. Graves
Claire E. Graves
JMJarrett Moyer
Jarrett Moyer
MZMichael J. Zobel
Michael J. Zobel
RMRoberto Mora
Roberto Mora
DSDerek Smith
Derek Smith
BPBenjamin E. Padilla
Benjamin E. Padilla

1 August 2019 in Seminars in Pediatric Surgery
Verified
Journal Article
Closed access
MZMichael Zobel
Michael Zobel
RGRebecca Gologorsky
Rebecca Gologorsky
HLHanmin Lee
Hanmin Lee
LVLan Vu
Lan Vu

23 November 2019 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
MZMichael J. Zobel
Michael J. Zobel
CEClifton Ewbank
Clifton Ewbank
RMRoberta Mora
Roberta Mora
OIOlajire Idowu
Olajire Idowu
Sung-Hoon KimSung-Hoon Kim
Sung-Hoon Kim
BPBenjamin E. Padilla
Benjamin E. Padilla

1 August 2020 in Journal of Surgical Research
Verified
Journal Article
Closed access
MZMichael J. Zobel
Michael J. Zobel
RLRoger Long
Roger Long
JGJessica Gosnell
Jessica Gosnell
JSJulie Ann Sosa
Julie Ann Sosa
BPBenjamin E. Padilla
Benjamin E. Padilla

1 January 2019 in JAMA Surgery
Verified
Journal Article
Closed access
PDF file
RWRussell G. Witt
Russell G. Witt
MZMichael Zobel
Michael Zobel
BPBenjamin Padilla
Benjamin Padilla
HLHanmin Lee
Hanmin Lee
TMTippi C. MacKenzie
Tippi C. MacKenzie
LVLan Vu
Lan Vu
Importance Sutureless gastroschisis repair offers an alternative to the traditional sutured method and has been associated with decreased intubation time. Published study results are inconsistent regarding the advantages of sutureless closure. Objective To compare the clinical outcomes of sutureless and sutured gastroschisis repair. Design, Setting, and Participants A single-center cohort review was performed of all consecutive patients (n = 97) who underwent gastroschisis repair from February 1, 2007, to April 30, 2017, at the University of California, San Francisco. Patients’ medical records were evaluated for clinical characteristics and outcomes. Cases with incomplete data during initial hospitalization were excluded. Main Outcomes and Measures Length of hospital stay, time to full enteral feeds, total parenteral nutrition duration, days requiring intravenous analgesia, days intubated, wound infection rate, antibiotic treatment duration, rate of umbilical hernias that required an operation, and readmission rate. Results In total, 97 patients (47 [48%] were female and 50 [52%] were male with a mean [SD] age of 2.8 [2.8] days) underwent gastroschisis repair, of which 7 were excluded for incomplete medical record. Of the 90 patients included in the study, 50 (56%) underwent sutured closure and 40 (44%) underwent sutureless closure. No statistical difference was found between the sutured and sutureless groups in length of hospital stay (mean [SD] days, 43.9 [40.4] vs 36.7 [21.2];P = .71), time to full enteral feeds (mean [SD] days, 31.4 [20.2] vs 27.9 [17.3];P = .22), total parenteral nutrition duration (mean [SD] days, 33.5 [29.8] vs 27.4 [18.2];P = .23), wound infection rates (14 [28%] vs 10 [25%];P = .81), and readmission rates (5 [10%] vs 7 [18%];P = .36). The sutureless group, compared with the sutured group, had substantially fewer days receiving antibiotics (mean [SD], 7.2 [6.4] vs 12.4 [13.2];P = .003), fewer days intubated (mean [SD], 2.8 [3.3] vs 6.8 [1.3];P = .001), fewer days receiving intravenous analgesia (mean [SD], 4.2 [4.0] vs 7.1 [4.5];P = .003), and fewer patients that required silo reduction (25 [63%] vs 48 [96%];P < .001). Sutureless closures, compared with the sutured technique, had considerably more umbilical hernias requiring surgical repair (5 [13%] vs 0;P = .02). Conclusions and Relevance Sutureless repair of gastroschisis appears to be associated with a statistically significant reduction in mechanical ventilation duration and pain medication requirements but may increase umbilical hernia risk. Multicenter randomized clinical trials are necessary to determine the true advantages of the sutureless approach.

1 December 2013 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
SSScott S Short
Scott S Short
JWJin Wang
Jin Wang
SCShannon L Castle
Shannon L Castle
GFG Esteban Fernandez
G Esteban Fernandez
NSNancy Smiley
Nancy Smiley
HFHenri R Ford
Henri R Ford
The intestinal barrier becomes compromised during systemic inflammation, leading to the entry of luminal bacteria into the host and gut origin sepsis. Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study, we examined the role of cyclooxygenase-2 (COX-2), a key enzyme in the production of inflammatory prostanoids, in gut barrier failure during experimental peritonitis in mice. I.p. injection of LPS or cecal ligation and puncture (CLP) increased the levels of COX-2 and its product prostaglandin E2 (PGE2) in the ileal mucosa, caused pathologic sloughing of the intestinal epithelium, increased passage of FITC-dextran and bacterial translocation across the barrier, and increased internalization of the tight junction (TJ)-associated proteins junction-associated molecule-A and zonula occludens-1. Luminal instillation of PGE2 in an isolated ileal loop increased transepithelial passage of FITC-dextran. Low doses (0.5–1 mg/kg), but not a higher dose (5 mg/kg) of the specific COX-2 inhibitor Celecoxib partially ameliorated the inflammatory gut barrier failure. These results demonstrate that high levels of COX-2-derived PGE2 seen in the mucosa during peritonitis contribute to gut barrier failure, presumably by compromising TJs. Low doses of specific COX-2 inhibitors may blunt this effect while preserving the homeostatic function of COX-2-derived prostanoids. Low doses of COX-2 inhibitors may find use as an adjunct barrier-protecting therapy in critically ill patients.